A recent study published in Scientific Reports indicates that a COVID-19 infection could increase the risk of developing pulmonary hypertension (PH), a serious and potentially fatal condition affecting blood pressure in the lungs.
The research found that individuals who contracted COVID-19 were more likely to develop obstructive sleep apnea (OSA) up to 4.5 years after the infection. OSA occurs when the upper airway partially or completely closes during sleep, leading to repeated interruptions in breathing.
Furthermore, the study observed that patients who developed post-COVID OSA also showed a higher likelihood of experiencing heart failure and pulmonary hypertension. This connection highlights a potential long-term cardiovascular consequence of COVID-19.
Understanding Pulmonary Hypertension
Pulmonary hypertension is a type of high blood pressure specifically affecting the pulmonary arteries, which transport blood from the heart to the lungs. In PH, this elevated pressure damages the pulmonary arteries, causing them to narrow and restricting blood flow. This forces the right ventricle of the heart to work harder to pump blood to the lungs, which can eventually weaken the heart muscle and lead to enlargement of the right ventricle, ultimately resulting in right-sided heart failure.
PH is a progressive disease that, without treatment, can be fatal. Experts estimate that it affects approximately 1 in 100 people globally. While it is more common in individuals over 65, it can affect people of all ages, including children and newborns.
Risk Factors and Symptoms
Several factors can increase the risk of developing pulmonary hypertension. These include a family history of the condition or blood-clotting disorders. Lifestyle and environmental factors such as smoking, obesity, exposure to asbestos, congenital heart defects, the use of illicit stimulants, and living at high altitudes are also associated with an increased risk.
Symptoms of pulmonary hypertension often develop gradually over months or years and can include swelling in the ankles, legs, and abdomen; shortness of breath; chest pressure or pain; dizziness; fatigue; a pounding heartbeat; loss of appetite; fainting; and a blue or gray tint to the skin. Due to the nonspecific nature of these symptoms, medical evaluation is crucial for an accurate diagnosis.
Potential complications of PH include heart enlargement and failure, irregular heart rhythms (arrhythmia), blood clots, bleeding in the lungs, and life-threatening issues for pregnant individuals.
Diagnosis and Treatment
Pulmonary hypertension is diagnosed through a combination of physical examinations and diagnostic tests. A physical exam may involve measuring vital signs, listening to the heart and lungs, checking for swelling, and examining neck veins for signs of heart failure. Diagnostic tests can include blood tests, chest CT scans and X-rays, VQ scans, Doppler echocardiograms, and right heart catheterization. A six-minute walk test may also be used to assess blood oxygen levels during physical activity.
While there is currently no cure for PH, various treatments can help manage the condition, improve quality of life, and prolong survival. Treatment options may include medications such as Phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonists, and prostacyclin analogs. Emerging research is also exploring the potential of GLP-1 drugs for treating PH. Lifestyle recommendations often include reducing salt intake and focusing on a diet rich in fiber, potassium, and magnesium.
The prognosis for individuals with PH varies depending on the specific type of PH, the stage at which it is diagnosed, and the presence of other health conditions.